MARKET

CFRX

CFRX

Contrafect Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.375
+0.135
+4.17%
Opening 14:35 05/26 EDT
OPEN
3.220
PREV CLOSE
3.240
HIGH
3.500
LOW
3.210
VOLUME
52.89K
TURNOVER
146.69K
52 WEEK HIGH
4.755
52 WEEK LOW
2.110
MARKET CAP
132.75M
P/E (TTM)
-3.7667
1D
5D
1M
3M
1Y
5Y
CFRX: Results from Interim Futility Analysis in July 2022…
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT
Benzinga · 3h ago
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former...
GlobeNewswire · 3d ago
ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as...
GlobeNewswire · 6d ago
Contrafect GAAP EPS of -$0.51
Contrafect press release (NASDAQ:CFRX): Q1 GAAP EPS of -$0.51. Cash and cash equivalents of $9.6M
Seekingalpha · 05/16 12:45
ContraFect: Q1 Earnings Insights
  ContraFect (NASDAQ:CFRX) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/16 12:29
BRIEF-ContraFect Reports Q1 Loss Per Share $0.51
reuters.com · 05/16 12:29
ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update
Phase 3 DISRUPT study achieves enrollment of MRSA patients necessary for DSMB to conduct interim futility analysisYONKERS, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on ...
GlobeNewswire · 05/16 11:30
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/09 12:18
More
No Data
Learn about the latest financial forecast of CFRX. Analyze the recent business situations of Contrafect Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CFRX stock price target is 11.92 with a high estimate of 23.00 and a low estimate of 6.50.
High23.00
Average11.92
Low6.50
Current 3.375
EPS
Actual
Estimate
-0.41-0.31-0.20-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 81
Institutional Holdings: 28.77M
% Owned: 73.15%
Shares Outstanding: 39.33M
TypeInstitutionsShares
Increased
14
614.06K
New
12
227.53K
Decreased
11
302.69K
Sold Out
8
265.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.18%
Pharmaceuticals & Medical Research
+0.47%
Key Executives
Chairman/President/Chief Executive Officer/Director
Roger Pomerantz
Vice Chairman/Director
Steven Gilman
Chief Financial Officer/IR Contact Officer
Michael Messinger
Executive Vice President
Cara Cassino
General Counsel/Secretary
Natalie Bogdanos
Lead Director
Sol Barer
Independent Director
Lishan Aklog
Independent Director
Jane Barlow
Independent Director
David Low
Independent Director
Michael Otto
Independent Director
Cary Sucoff
No Data
No Data
About CFRX
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infection. Its lead DLA candidate includes exebacase, which is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia, and osteomyelitis. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. The Company is conducting Phase II clinical study of exebacase for the treatment of Staph aureus bacteremia, including right-sided endocarditis, caused by MRSA or MSSA.

Webull offers kinds of ContraFect Corp stock information, including NASDAQ:CFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CFRX stock methods without spending real money on the virtual paper trading platform.